Condition: Advanced Solid Tumor · Sponsor: Senhwa Biosciences, Inc.
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, preliminary evidence of antitumor effect and the effect of CX-5461 on the Health-Related Quality of Life (HRQoL) will also be evaluated. The study will also evaluate the predictive value of mutational signatures and explore the significance of dynamic changes in ctDNA levels and plasma DNA methylome profiling in this study's exploratory cohort.
This description comes directly from the study's public registry record.
Hylee Lee · 886-2-889119856 · hylee@senhwabio.com
Jenny Chen · jennychen@senhwabio.com
Always discuss trial participation with your own doctor first.
| University of California, Los Angeles | Santa Monica, California, United States | Recruiting |
| H. Lee Moffitt Cancer Center and Research Institute Hospital | Tampa, Florida, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan-Kettering Cancer Center | New York, New York, United States | Withdrawn |
| Ohio State University-James Cancer Hospital and Solove Research Institute | Columbus, Ohio, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| Centre hospitalier de l'Université de Montréal (CHUM) | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04890613